Track Stealth BioTherapeutics's long-term debt ($14M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2022), MITO shows a long-term debt of $14M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MITO's long-term debt is now $14M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Stealth BioTherapeutics is outperforming or lagging.
Tracking MITO's long-term debt over time shows whether Stealth BioTherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $14M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Stealth BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $14M) with ownership activity and broader fundamentals.
Stealth BioTherapeutics's long-term debt is $14M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.